120 related articles for article (PubMed ID: 15109631)
1. Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.
Rueeger H; Gerspacher M; Buehlmayer P; Rigollier P; Yamaguchi Y; Schmidlin T; Whitebread S; Nuesslein-Hildesheim B; Nick H; Cricione L
Bioorg Med Chem Lett; 2004 May; 14(10):2451-7. PubMed ID: 15109631
[TBL] [Abstract][Full Text] [Related]
2. Novel potent antagonists of human neuropeptide Y-Y5 receptor. Part 4: tetrahydrodiazabenzazulene derivatives.
Satoh Y; Hatori C; Ito H
Bioorg Med Chem Lett; 2002 Apr; 12(7):1009-11. PubMed ID: 11909705
[TBL] [Abstract][Full Text] [Related]
3. Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 2: substituted benzo[a]cycloheptene derivatives.
Itani H; Ito H; Sakata Y; Hatakeyama Y; Oohashi H; Satoh Y
Bioorg Med Chem Lett; 2002 Mar; 12(5):757-61. PubMed ID: 11858996
[TBL] [Abstract][Full Text] [Related]
4. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists.
Sato N; Takahashi T; Shibata T; Haga Y; Sakuraba A; Hirose M; Sato M; Nonoshita K; Koike Y; Kitazawa H; Fujino N; Ishii Y; Ishihara A; Kanatani A; Fukami T
J Med Chem; 2003 Feb; 46(5):666-9. PubMed ID: 12593644
[TBL] [Abstract][Full Text] [Related]
6. Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.
Brothers SP; Saldanha SA; Spicer TP; Cameron M; Mercer BA; Chase P; McDonald P; Wahlestedt C; Hodder PS
Mol Pharmacol; 2010 Jan; 77(1):46-57. PubMed ID: 19837904
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.
Pizzi DA; Leslie CP; Mazzali A; Seri C; Biagetti M; Bentley J; Genski T; Di Fabio R; Contini S; Sabbatini FM; Zonzini L; Caberlotto L
Bioorg Med Chem Lett; 2010 Dec; 20(23):7120-3. PubMed ID: 20951033
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
[TBL] [Abstract][Full Text] [Related]
9. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists.
Sakamoto T; Moriya M; Haga Y; Takahashi T; Shibata T; Okamoto O; Nonoshita K; Kitazawa H; Hidaka M; Gomori A; Iwaasa H; Ishihara A; Kanatani A; Fukami T; Gao YD; Macneil DJ; Yang L
Bioorg Med Chem Lett; 2009 Mar; 19(6):1564-8. PubMed ID: 19243937
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.
Packiarajan M; Marzabadi MR; Desai M; Lu Y; Noble SA; Wong WC; Jubian V; Chandrasena G; Wolinsky TD; Zhong H; Walker MW; Wiborg O; Andersen K
Bioorg Med Chem Lett; 2011 Sep; 21(18):5436-41. PubMed ID: 21782428
[TBL] [Abstract][Full Text] [Related]
12. [Research progress of selective mGluR1 antagonists].
Yang YL; Sun W; Peng C; Zhang XY; Yang XH
Yao Xue Xue Bao; 2011 Oct; 46(10):1167-72. PubMed ID: 22242445
[TBL] [Abstract][Full Text] [Related]
13. Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.
Haga Y; Sakamoto T; Shibata T; Nonoshita K; Ishikawa M; Suga T; Takahashi H; Takahashi T; Takahashi H; Ando M; Murai T; Gomori A; Oda Z; Kitazawa H; Mitobe Y; Kanesaka M; Ohe T; Iwaasa H; Ishii Y; Ishihara A; Kanatani A; Fukami T
Bioorg Med Chem; 2009 Oct; 17(19):6971-82. PubMed ID: 19720539
[TBL] [Abstract][Full Text] [Related]
14. Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.
Leslie CP; Bentley J; Biagetti M; Contini S; Di Fabio R; Donati D; Genski T; Guery S; Mazzali A; Merlo G; Pizzi DA; Sacco F; Seri C; Tessari M; Zonzini L; Caberlotto L
Bioorg Med Chem Lett; 2010 Oct; 20(20):6103-7. PubMed ID: 20813523
[TBL] [Abstract][Full Text] [Related]
15. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
Kanatani A; Ishihara A; Iwaasa H; Nakamura K; Okamoto O; Hidaka M; Ito J; Fukuroda T; MacNeil DJ; Van der Ploeg LH; Ishii Y; Okabe T; Fukami T; Ihara M
Biochem Biophys Res Commun; 2000 May; 272(1):169-73. PubMed ID: 10872822
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
[TBL] [Abstract][Full Text] [Related]
18. Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives.
Itani H; Ito H; Sakata Y; Hatakeyama Y; Oohashi H; Satoh Y
Bioorg Med Chem Lett; 2002 Mar; 12(5):799-802. PubMed ID: 11859006
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
[TBL] [Abstract][Full Text] [Related]
20. (9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.
Sato N; Jitsuoka M; Shibata T; Hirohashi T; Nonoshita K; Moriya M; Haga Y; Sakuraba A; Ando M; Ohe T; Iwaasa H; Gomori A; Ishihara A; Kanatani A; Fukami T
J Med Chem; 2008 Aug; 51(15):4765-70. PubMed ID: 18637668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
